Octahydrocurcumin
Based on 1 publication(s) in Google Scholar
Octahydrocurcumin (Hexahydrobisdemethoxycurcumin) is an orally active anticancer and anti-inflammatory agent, and is the final hydrogenated metabolite of Curcumin (HY-N0005) in vivo. Octahydrocurcumin exerts its anti-tumor and anti-inflammatory effects by inducing the mitochondrial apoptosis pathway and inhibiting the TAK1-NF-κB-COX-2 pathway, respectively.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.25%
- CAS No.: 36062-07-4
- 화학식: C21H28O6
- 분자량:376.44
-
보관:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Octahydrocurcumin
MoreAll MAP4K Isoforms
More
Biological Activity
|
COX-2 |
TAK1 |
Octahydrocurcumin (10-40 mg/kg; i.g.; daily; 7 days) dose-dependently inhibits xylene-induced mouse ear edema, achieving a maximum suppression rate of 70.67% at 40 mg/kg[2].
Octahydrocurcumin (10-40 mg/kg; i.g.; daily; 7 days) dose-dependently reduces acetic acid-induced vascular permeability in mice, reaching a 48.0% suppression rate at 40 mg/kg[2].
Octahydrocurcumin (10-40 mg/kg; i.g.; daily; 7 days) dose-dependently inhibits Carrageenan (HY-125474)-induced mouse paw edema, reduces pro-inflammatory mediator production, selectively suppresses COX-2 expression, and blocks the TAK1-NF-κB pathway[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Kunming (KM) (male, 18-22 g, intraperitoneal injection of H22 cell suspension to establish HCC ascites model)[1]
-
Dosage:5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:i.g.; daily; 7 days
-
Result:Increased survival rates by 26.13%, 50%, and 78.98% respectively compared to vehicle control; 20 mg/kg dose resulted in a significantly higher survival rate than 100 mg/kg curcumin.
Suppressed increases in body weight and abdominal circumference compared to vehicle control; 20 mg/kg dose resulted in significantly lower body weight and abdominal circumference than 100 mg/kg curcumin on day 7.
Showed no significant difference in spleen and thymus indexes compared to intact, vehicle, and curcumin groups at 20 mg/kg dose.
Reduced ascites volume significantly more than 100 mg/kg curcumin at 20 mg/kg dose.
Reduced cancer cellular viability significantly more than 100 mg/kg curcumin at 20 mg/kg dose.
Significantly increased the apoptotic rate of ascitic cells compared to 100 mg/kg curcumin at 20 mg/kg dose.
Upregulated p53, Bax, Bad, cytochrome C, cleaved caspase-9, cleaved caspase-3, and cleaved PARP protein expressions, and downregulated MDM2, Bcl-2, and Bcl-xl protein expressions to a greater extent than 100 mg/kg curcumin at 20 mg/kg dose; also upregulated Bax mRNA and downregulated Bcl-2 mRNA expression.
-
Animal Model:ICR mice (male and female, 18-22 g)[2]
-
Dosage:10 mg/kg; 20 mg/kg; 40 mg/kg
-
Administration:i.g.; daily; 7 days
-
Result:Inhibited ear edema with suppression rates of 37.33%, 57.33%, and 70.67% at 10, 20, and 40 mg/kg, respectively.\nInhibited vascular permeability with a maximum suppression ratio of 48.0% at 40 mg/kg.\nAttenuated paw edema dose-dependently from 1 to 6 hours post-carrageenan injection.
Exhibited edema inhibition ratios of 35.87% at 4 hours, 45.16% at 5 hours, and 53.41% at 6 hours at 40 mg/kg.
Significantly reduced carrageenan-induced increases in IL-1β, IL-6, TNF-α, and PGE2 levels at 40 mg/kg, with greater inhibitory activity than curcumin.
Selectively downregulated COX-2 gene and protein expression without affecting COX-1 at 40 mg/kg.
Inhibited TAK1 phosphorylation, reduced TAB1 protein expression, suppressed IKKβ and IκBα phosphorylation, and prevented NF-κB (p65) translocation from the cytosol to the nucleus at 40 mg/kg.
Chemical Information
-
CAS No. 36062-07-4
-
Appearance Solid-Liquid Mixture
-
분자량 376.44
-
화학식 C21H28O6
-
Color Light yellow to yellow
-
SMILES
OC(CC(O)CCC1=CC=C(O)C(OC)=C1)CCC2=CC=C(O)C(OC)=C2
-
Synonyms
Hexahydrobisdemethoxycurcumin
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
용액&용해도
DMSO : 100 mg/mL (265.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 10 mg/mL (26.56 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3.75 mg/mL (9.96 mM); Clear solution
This protocol yields a clear solution of ≥ 3.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (37.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 3.75 mg/mL (9.96 mM); Clear solution
This protocol yields a clear solution of ≥ 3.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (37.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (282 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhang Z , et al. Octahydrocurcumin, a final hydrogenated metabolite of curcumin, possesses superior anti-tumor activity through induction of cellular apoptosis. Food Funct. 2018;9(4):2005-2014. [Content Brief]
[2]. Zhang ZB, et al. Curcumin's Metabolites, Tetrahydrocurcumin and Octahydrocurcumin, Possess Superior Anti-inflammatory Effects in vivo Through Suppression of TAK1-NF-κB Pathway. Front Pharmacol. 2018;9:1181. Published 2018 Oct 17. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 2.6565 mL | 13.2823 mL | 26.5647 mL | 66.4116 mL |
| 5 mM | 0.5313 mL | 2.6565 mL | 5.3129 mL | 13.2823 mL | |
| 10 mM | 0.2656 mL | 1.3282 mL | 2.6565 mL | 6.6412 mL | |
| 15 mM | 0.1771 mL | 0.8855 mL | 1.7710 mL | 4.4274 mL | |
| 20 mM | 0.1328 mL | 0.6641 mL | 1.3282 mL | 3.3206 mL | |
| 25 mM | 0.1063 mL | 0.5313 mL | 1.0626 mL | 2.6565 mL | |
| DMSO | 30 mM | 0.0885 mL | 0.4427 mL | 0.8855 mL | 2.2137 mL |
| 40 mM | 0.0664 mL | 0.3321 mL | 0.6641 mL | 1.6603 mL | |
| 50 mM | 0.0531 mL | 0.2656 mL | 0.5313 mL | 1.3282 mL | |
| 60 mM | 0.0443 mL | 0.2214 mL | 0.4427 mL | 1.1069 mL | |
| 80 mM | 0.0332 mL | 0.1660 mL | 0.3321 mL | 0.8301 mL | |
| 100 mM | 0.0266 mL | 0.1328 mL | 0.2656 mL | 0.6641 mL |
Octahydrocurcumin Related Classifications
HY-N0894 Related Classifications
Powered by Bioz